Differences in Quality of Life Between Bendamustine-Rituximab and R-CHOP/R-CVP in Patients With Previously Untreated Advanced Indolent Non-Hodgkin Lymphoma or Mantle Cell Lymphoma

摘要

Comparative chemotherapy-related quality of life data are lacking. Bendamustine-rituximab (BR) demonstrated noninferiority to R-CHOP (rituximab/cyclophosphamide/doxorubicin/vincristine/prednisone)/R-CVP (rituximab/cyclophosphamide/vincristine/prednisone) in first-line advanced indolent non-Hodgkin and mantle cell lymphomas. Patients receiving BR reported improvement across many domains, with a few exceptions, of the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30.